Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) insider Mike Mensinger sold 2,650 shares of the firm’s stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $22.00, for a total value of $58,300.00. Following the completion of the transaction, the insider directly owned 174,740 shares in the company, valued at $3,844,280. The trade was a 1.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Mike Mensinger also recently made the following trade(s):
- On Wednesday, September 16th, Mike Mensinger sold 2,650 shares of Beta Bionics stock. The shares were sold at an average price of $22.00, for a total transaction of $58,300.00.
- On Wednesday, September 2nd, Mike Mensinger sold 4,375 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total transaction of $83,606.25.
Beta Bionics Price Performance
Shares of BBNX stock opened at $16.75 on Friday. The company has a market cap of $910.65 million, a price-to-earnings ratio of -9.10 and a beta of 3.39. Beta Bionics, Inc. has a 1 year low of $8.80 and a 1 year high of $32.71. The firm has a fifty day moving average price of $19.11 and a 200-day moving average price of $14.89.
Beta Bionics (NASDAQ:BBNX – Get Free Report) last released its earnings results on Tuesday, October 27th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.01. Beta Bionics had a negative return on equity of 27.33% and a negative net margin of 65.31%. The company had revenue of $35.51 million for the quarter. Equities research analysts expect that Beta Bionics, Inc. will post -2.03 EPS for the current year.
Key Stories Impacting Beta Bionics
Here are the key news stories impacting Beta Bionics this week:
- Positive Sentiment: Quarterly results slightly beat expectations. Beta Bionics reported a third-quarter loss of $0.52 per share, better than the $0.53 consensus estimate, while revenue of $35.51 million exceeded analysts’ expectations of approximately $34.7 million. The company also updated its 2026 guidance, although details were not provided. Beta Bionics third-quarter results
- Positive Sentiment: Analyst sentiment remains generally favorable. Stifel Nicolaus maintained a Buy rating, and several firms have raised price targets. MarketBeat data shows a Moderate Buy consensus and an average target of $23.69, above the recent trading level.
- Neutral Sentiment: Institutional ownership news was mixed but included notable purchases. BlackRock, Bank of America and other investment firms recently initiated or increased positions in Beta Bionics. Such activity may provide some support, but the reported purchases largely reflect earlier quarters rather than a new catalyst.
- Neutral Sentiment: Insiders continued to sell relatively small portions of their holdings. Director Mark Hopman sold 821 shares for about $16,420, while insider Mike Mensinger sold 2,650 shares for approximately $58,300. Both retained substantial positions, limiting the significance of the transactions, though repeated insider selling can weigh on investor sentiment. SEC insider filing
- Negative Sentiment: Multiple law firms reiterated a securities class-action deadline of November 3, 2026. The lawsuit covers investors who purchased BBNX securities from July 30, 2025, through February 24, 2026. The unusually large number of investor-law-firm notices increases legal, reputational and potential financial risks for Beta Bionics.
- Negative Sentiment: The allegations center on FDA compliance and iLet safety disclosures. Notices allege that Beta Bionics did not fully disclose information related to an FDA warning, quality-system issues and more than 18,000 iLet complaints, including potentially serious hypoglycemia incidents. These claims have not been proven, but possible litigation costs, regulatory action or additional product concerns could pressure the stock. Beta Bionics securities class action notice
- Negative Sentiment: Execution risks could cloud future growth. The company has disclosed challenges associated with the commercial launch of its next-generation Mint patch pump, adding uncertainty to its growth outlook.
Institutional Trading of Beta Bionics
Large investors have recently made changes to their positions in the stock. Squarepoint Ops LLC bought a new stake in shares of Beta Bionics in the second quarter valued at about $2,524,000. Bank of America Corp DE bought a new position in Beta Bionics in the second quarter worth approximately $8,566,000. Man Group plc bought a new stake in Beta Bionics during the 2nd quarter valued at $419,000. Legal & General Group Plc purchased a new position in shares of Beta Bionics in the 2nd quarter valued at $62,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Beta Bionics in the 2nd quarter valued at about $172,000.
Analyst Ratings Changes
A number of brokerages have issued reports on BBNX. Bank of America lifted their price target on shares of Beta Bionics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Tuesday, September 15th. Jefferies Financial Group started coverage on Beta Bionics in a research note on Monday, October 12th. They set a “buy” rating and a $30.00 price target for the company. Piper Sandler reaffirmed an “overweight” rating and set a $24.00 price target (up from $20.00) on shares of Beta Bionics in a research note on Wednesday. Barclays began coverage on shares of Beta Bionics in a report on Tuesday, October 6th. They issued an “overweight” rating and a $30.00 target price on the stock. Finally, Wall Street Zen lowered Beta Bionics from a “hold” rating to a “strong sell” rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Beta Bionics currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.69.
Read Our Latest Report on BBNX
About Beta Bionics
Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.
The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual’s glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.
Featured Stories
- Five stocks we like better than Beta Bionics
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
